|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Molar mass||835.93 g/mol|
|(what is this?)|
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[unreliable source?]
In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%).
- "Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review" (Press release). sanofi-aventis. 2010-06-17. Retrieved June 17, 2010.
- "Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere".
- Cabazitaxel - Official web site of manufacturer.
- Cabazitaxel Prescribing Information - Official prescribing information.
- U.S. National Library of Medicine: Drug Information Portal - Cabazitaxel
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|